Bis-2-tetrahydropyranylsulfid | 51380-90-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: Bis-2-tetrahydropyranylsulfid
• 英文别名: Tetrahydropyranyl thioether；2-(oxan-2-ylsulfanyl)oxane
• CAS: 51380-90-6
• 化学式: C₁₀H₁₈O₂S
• 分子量: 202.318
• InChiKey: XWOYCQCJZYOINY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  43.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Nitrosated and nitrosylated taxanes, compositions and methods of use
  申请人：——

  公开号：US20020010146A1

  公开（公告）日：2002-01-24

  The present invention describes novel nitrosated and/or nitrosylated taxanes, and novel compositions comprising at least one nitrosated and/or nitrosylated taxane, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The present invention also provides novel compositions comprising at least one taxane and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The compounds and compositions of the present invention can also be bound to a matrix. The present invention also provides methods for treating or preventing cardiovascular diseases and disorders, autoimmune diseases, pathological conditions resulting from abnormal cell proliferation, polycystic kidney disease, inflammatory disease, preserving organs and/or tissues or to inhibit wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis, by administering nitrosated and/or nitrosylated taxane or parent taxanes in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions.

  本发明描述了新型亚硝化和/或亚硝基化紫杉醇，以及包含至少一种亚硝化和/或亚硝基化紫杉醇的新型组合物，以及可选地包含至少一种供体、转移或释放一氧化氮、提高内源性内皮衍生松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的化合物。本发明还提供了包含至少一种紫杉醇和至少一种供体、转移或释放一氧化氮、提高内源性内皮衍生松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。本发明的化合物和组合物也可以与基质结合。本发明还提供了治疗或预防心血管疾病和障碍、自身免疫疾病、由异常细胞增殖导致的病理情况、多囊肾病、炎症性疾病、保护器官和/或组织或抑制伤口收缩的方法，特别是通过在生理条件下向靶位点施用能够释放一氧化氮或间接传递或转移一氧化氮至靶位点的亚硝化和/或亚硝基化紫杉醇或母体紫杉醇与能够释放一氧化氮的一氧化氮供体的组合物进行预防性和/或治疗性治疗，尤其是对再狭窄的预防性和/或治疗性治疗。
• Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
  申请人：——

  公开号：US20020143007A1

  公开（公告）日：2002-10-03

  The present invention describes novel nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one &agr;-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

  本发明描述了新型硝化和/或硝基化α-肾上腺素受体拮抗剂，以及包含至少一种硝化和/或硝基化α-肾上腺素受体拮抗剂的新型组合物，以及可选地包含一种或多种捐赠、转移或释放一氧化氮、提高内源性内皮衍生松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合成酶底物的化合物，和/或一种或多种血管活性药物。本发明还提供了包含至少一种α-肾上腺素受体拮抗剂和一种或多种捐赠、转移或释放一氧化氮、提高内源性内皮衍生松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合成酶底物，和/或一种或多种血管活性药物的新型组合物。本发明还提供了用于治疗或预防男性和女性的性功能障碍、增强男性和女性的性反应，以及治疗或预防良性前列腺增生、高血压、充血性心力衰竭、变异性（Printzmetal）心绞痛、青光眼、神经退行性疾病、血管痉挛性疾病、认知障碍、急迫性尿失禁或过度活跃膀胱，以及逆转麻醉状态的方法。
• Phosphodiesterase inhibitor compounds and nitric oxide donors
  申请人：Garvey S. David

  公开号：US20060063774A1

  公开（公告）日：2006-03-23

  The invention provides phosphodiesterase inhibitors and/or nitric oxide donors that are useful in treating male impotence, female sexual dysfunction and anal diseases.

  该发明提供了对男性阳痿、女性性功能障碍和肛门疾病有用的磷酸二酯酶抑制剂和/或一氧化氮供体。
• H2 RECEPTOR ANTAGONIST COMPOUNDS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSTIONS AND METHODS OF USE
  申请人：——

  公开号：US20020077343A1

  公开（公告）日：2002-06-20

  The present invention describes novel nitrosated and/or nitrosylated H 2 receptor antagonist compounds, and novel compositions comprising at least one H 2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO 2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase. The present invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H 2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.

  本发明描述了新型的硝化和/或亚硝化H2受体拮抗剂化合物，以及包含至少一种H2受体拮抗剂化合物的新型组合物，该化合物可以选择性地取代至少一个NO和/或NO2基团，并且可以选择性地包含至少一种捐赠、转移或释放一氧化氮的化合物，刺激内源性一氧化氮合成，提高内源性内皮源性松弛因子水平或是一氧化氮合酶的底物。本发明还描述了治疗和/或预防胃肠道疾病的方法；改善H2受体拮抗剂的胃保护性能；减少溃疡的复发；促进溃疡愈合；预防和/或治疗炎症和微生物感染、眼科疾病和障碍、多发性硬化症和病毒感染；减少或降低非甾体抗炎化合物使用所带来的胃肠道毒性。
• Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
  申请人：——

  公开号：US20030158184A1

  公开（公告）日：2003-08-21

  The invention provides methods for treating female sexual dysfunctions by administering to a female individual a therapeutically effective amount of at least one compound that donates, transfers or release nitrogen monoxide, that induces the production of endogenous endothelium-derived relaxing factor, that stimulates endogenous synthesis of nitrogen monoxide, or that is a substrate for nitric oxide synthase. The methods may further comprise administering a therapeutically effective amount of a phosphodiesterase inhibitor and/or a nitrosated and/or nitrosylated phosphodiesterase inhibitor.

  本发明提供了一种通过向女性个体施用至少一种捐赠、转移或释放一氧化氮的化合物，诱导内源性内皮源性松弛因子的产生，刺激内源性一氧化氮的合成，或者是一氧化氮合酶的底物的治疗有效量，来治疗女性性功能障碍的方法。该方法还可以进一步包括施用治疗有效量的磷酸二酯酶抑制剂和/或硝化和/或硝酰化的磷酸二酯酶抑制剂。